Skip to content

Role of occlusion of uterine openings in preventing tumour spillage during surgery in endometrial cancer.

Role of tubal and cervical os occlusion in preventing intra-operative tumour spillage in endometrial cancer- a pilot study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042348
Enrollment
40
Registered
2022-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Fallopian tube and cervical os ligation: Technique for tubal occlusion- tying the fimbrial end with 2-0 silk suture after applying right-angle forceps. Technique for cervical os occlusi

Sponsors

Dr B Barooah Cancer Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Epithelial endometrial cancer- endometrioid, papillary serous, clear-cell, squamous, mucinous, undifferentiated, carcino-sarcoma Surgery as primary definitive treatment modality

Exclusion criteria

Exclusion criteria: Double primaries Uterine sarcomas Patients receiving neo-adjuvant chemotherapy/radiotherapy Previous h/o radiation to the pelvis Secondary uterine cancers Residual tumour History of tubal ligation

Design outcomes

Primary

MeasureTime frame
To analyse the rate of tumour cells dissemination during hysterectomy after fallopian tube and cervical os occlusion compared to non- interventional arm with the help of peritoneal and vaginal cytology in endometrial cancer. Timepoint: 15 days

Secondary

MeasureTime frame
Rate of positive peritoneal cytology (PPC) in endometrial cancer. Rate of abnormal endometrial cells detection on PAPs in endometrial cancer. Co-relation between PPC and other risk factors (histology, grade, LVSI, degree of myometrial infiltration) in endometrial cancer. Timepoint: 1 month

Countries

India

Contacts

Public ContactAparajita

Dr. B. Barooah Cancer Institute

drdbarmon@gmail.com9864066814

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026